[go: up one dir, main page]

CL2018000916A1 - Composiciones de silicato de zirconio de uso prolongado y métodos de uso de las mismas - Google Patents

Composiciones de silicato de zirconio de uso prolongado y métodos de uso de las mismas

Info

Publication number
CL2018000916A1
CL2018000916A1 CL2018000916A CL2018000916A CL2018000916A1 CL 2018000916 A1 CL2018000916 A1 CL 2018000916A1 CL 2018000916 A CL2018000916 A CL 2018000916A CL 2018000916 A CL2018000916 A CL 2018000916A CL 2018000916 A1 CL2018000916 A1 CL 2018000916A1
Authority
CL
Chile
Prior art keywords
zirconium silicate
methods
silicate compositions
prolonged
lead content
Prior art date
Application number
CL2018000916A
Other languages
English (en)
Inventor
Donald Jeffrey Keyser
Alvaro F Guillem
Original Assignee
Zs Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58227650&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2018000916(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zs Pharma Inc filed Critical Zs Pharma Inc
Publication of CL2018000916A1 publication Critical patent/CL2018000916A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/02—Processes using inorganic exchangers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00—Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08—Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/14—Base exchange silicates, e.g. zeolites
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C01B39/02—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
    • C01B39/02—Crystalline aluminosilicate zeolites; Isomorphous compounds thereof; Direct preparation thereof; Preparation thereof starting from a reaction mixture containing a crystalline zeolite of another type, or from preformed reactants; After-treatment thereof
    • C01B39/06—Preparation of isomorphous zeolites characterised by measures to replace the aluminium or silicon atoms in the lattice framework by atoms of other elements, i.e. by direct or secondary synthesis
    • C01B39/08—Preparation of isomorphous zeolites characterised by measures to replace the aluminium or silicon atoms in the lattice framework by atoms of other elements, i.e. by direct or secondary synthesis the aluminium atoms being wholly replaced
    • C01B39/085—Group IVB- metallosilicates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2004/00—Particle morphology
    • C01P2004/60—Particles characterised by their size
    • C01P2004/61—Micrometer sized, i.e. from 1-100 micrometer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Geology (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a composiciones de silicato de zirconio que tienen un contenido de plomo que está por debajo de 0.6 ppm y a métodos de fabricación de silicato de zirconio a volúmenes de reactor superiores a 200 L con un contenido de plomo de por debajo de 1,1 ppm. El contenido de plomo del silicato de zirconio de la presente invención se encuentra dentro de los niveles que se consideran aceptables para su uso prolongado, dados los requisitos de dosis para el silicato de zirconio.
CL2018000916A 2015-10-14 2018-04-10 Composiciones de silicato de zirconio de uso prolongado y métodos de uso de las mismas CL2018000916A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14/883,428 US9592253B1 (en) 2015-10-14 2015-10-14 Extended use zirconium silicate compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
CL2018000916A1 true CL2018000916A1 (es) 2018-08-17

Family

ID=58227650

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018000916A CL2018000916A1 (es) 2015-10-14 2018-04-10 Composiciones de silicato de zirconio de uso prolongado y métodos de uso de las mismas

Country Status (19)

Country Link
US (4) US9592253B1 (es)
EP (1) EP3362456A4 (es)
JP (1) JP6546700B2 (es)
KR (1) KR102667566B1 (es)
CN (2) CN108137620B (es)
AR (1) AR106369A1 (es)
AU (1) AU2016338753C1 (es)
CA (1) CA3000950C (es)
CL (1) CL2018000916A1 (es)
CR (1) CR20180276A (es)
EA (2) EA202091273A1 (es)
HK (1) HK1254808A1 (es)
IL (1) IL258478B (es)
MX (1) MX2018004440A (es)
MY (1) MY187088A (es)
PH (1) PH12018500786B1 (es)
TW (1) TWI742004B (es)
WO (1) WO2017066128A1 (es)
ZA (1) ZA201803095B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012214224B2 (en) 2011-02-11 2016-03-17 Zs Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof
WO2019092179A1 (en) * 2017-11-10 2019-05-16 Sandoz Ag Pharmaceutical compositions comprising zs-9
CN117137944A (zh) 2019-03-13 2023-12-01 阿斯利康(瑞典)有限公司 用于血液透析患者中使用的钾结合剂
CN117342570A (zh) * 2023-09-04 2024-01-05 杭州国瑞生物科技有限公司 一种环硅酸锆钠的a晶型及其制备方法
CN117735564B (zh) * 2023-12-19 2025-12-19 杭州国瑞生物科技有限公司 一种环硅酸锆钠的b晶型及其制备方法与应用
CN120172420B (zh) * 2025-03-21 2025-12-23 时森海(杭州)医药科技有限公司 控制粒径分布的环硅酸锆钠及其制备方法

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE21224E (en) 1939-10-03 Coherent zirconium silicates
US2809943A (en) * 1952-09-11 1957-10-15 Dow Chemical Co Weighted ion exchange resin granules and method of making same
US3492092A (en) * 1966-04-04 1970-01-27 Chem Separations Corp Ion exchange process for treating crude mineral solutions
US3947279A (en) 1971-12-23 1976-03-30 Owens-Illinois, Inc. Thermally crystallizable glasses possessing precision controlled crystallization and flow properties and process of producing same
US4581141A (en) 1978-02-27 1986-04-08 Purdue Research Foundation Dialysis material and method for removing uremic substances
FR2444005A1 (fr) 1978-12-15 1980-07-11 Ugine Kuhlmann Procede industriel de fabrication en semi-continu de zeolithe a
US4943545A (en) 1987-06-08 1990-07-24 Mobil Oil Corporation Activation of zeolites
US5015453A (en) 1989-04-28 1991-05-14 W. R. Grace & Co.-Conn. Crystalline group IVA metal-containing molecular sieve compositions
US5338527A (en) 1992-08-20 1994-08-16 Uop Zirconium silicate composition, method of preparation and uses thereof
WO1994010087A1 (en) 1992-10-28 1994-05-11 Crosfield Limited Silicas
US5518707A (en) 1994-10-24 1996-05-21 Uop Metallo germanates
WO1998052239A1 (fr) 1997-03-12 1998-11-19 Japan As Represented By Director General Of Agency Of Industrial Science And Technology Separateur pour accumulateur et accumulateur electrique alcalin l'utilisant
IT1283284B1 (it) 1996-03-21 1998-04-16 Eniricerche Spa Zeolite ers-10 e procedimento per la sua preparazione
FR2750893B1 (fr) 1996-07-12 1998-10-30 Elf Aquitaine Procede de synthese de zeolithe avec agitation homogene du milieu, dispositif et application
US5888472A (en) 1997-04-08 1999-03-30 Uop Llc Zirconium silicate molecular sieves and process using the same
US5891417A (en) 1997-04-08 1999-04-06 Uop Llc Zirconium silicate and zirconium germanate molecular sieves and process using the same
US6007790A (en) 1998-08-13 1999-12-28 Uop Llc Family of microporous indium silicate compositions
US6332985B1 (en) 1999-03-29 2001-12-25 Uop Llc Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
US6099737A (en) 1999-03-29 2000-08-08 Uop Llc Process for removing toxins from blood using zirconium metallate or titanium metallate compositions
US7041274B2 (en) 1999-10-22 2006-05-09 Intevep, S.A. Aluminosilicate compositions, preparation and use
US20020061521A1 (en) 2000-01-31 2002-05-23 Rosen Craig A. Nucleic acids, proteins, and antibodies
US6379641B1 (en) 2000-05-01 2002-04-30 Uop Llc Microporous rare earth silicates and method of producing same
US6596254B1 (en) 2000-06-12 2003-07-22 Sandia Corporation Niobate-based octahedral molecular sieves
WO2002062356A2 (en) 2001-02-06 2002-08-15 Ash Medical Systems, Inc. Monovalent-selective cation exchangers as oral sorbent therapy
US6579460B1 (en) 2001-03-13 2003-06-17 Uop Llc Process and composition for removing toxins from bodily fluids
US6814871B1 (en) 2001-07-13 2004-11-09 Uop Llc Process for removing pollutants from aqueous streams
US6689335B1 (en) 2002-12-19 2004-02-10 Eastman Kodak Company Silver ion sequester and release agent
EP1695760B1 (en) 2003-12-15 2020-01-01 Asahi Kasei Kabushiki Kaisha Porous formed article and method for production thereof
MXPA06011270A (es) 2004-03-30 2007-03-08 Ilypsa Inc Composiciones fijadoras de iones.
US8192758B2 (en) * 2004-03-30 2012-06-05 Relypsa, Inc. Ion binding compositions
CA2593525C (en) 2004-12-28 2011-05-10 Renal Solutions, Inc. Method of synthesizing zirconium phosphate particles
US7967984B2 (en) 2005-06-14 2011-06-28 Asahi Kasei Chemicals Corporation Apparatus for water treatment and method of treating water
WO2007041569A1 (en) 2005-09-30 2007-04-12 Ilypsa, Inc. Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal
CA2624112A1 (en) 2005-09-30 2007-04-05 Ilypsa, Inc. Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom
US7297318B2 (en) * 2005-11-17 2007-11-20 J.M. Huber Corporation Method of removing heavy metals from silicate sources during silicate manufacturing
US7201885B1 (en) * 2005-11-17 2007-04-10 J.M. Huber Corporation Method of removing heavy metals from silicate sources during silicate manufacturing
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
WO2007127390A2 (en) 2006-04-28 2007-11-08 Biolife, L.L.C. Materials and methods for wound treatment
EP2079660B1 (en) 2007-01-03 2017-01-11 Insilico Co., Ltd. Coordination polymer crystal with porous metal-organic frameworks and preperation method thereof
ES2304890B1 (es) 2007-04-03 2009-10-30 Universidad De Zaragoza Procedimiento de obtencion de esferas de titanosilicato.
DE202009018699U1 (de) 2008-02-26 2012-11-20 Corning Incorporated Läutermittel für Silikatgläser
WO2010022381A1 (en) 2008-08-22 2010-02-25 Relypsa, Inc. Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties
PL2365988T5 (pl) 2008-08-22 2019-11-29 Vifor Int Ltd Usieciowane polimery kationowymienne, kompozycje i zastosowanie w leczeniu hiperkaliemii
US8865121B2 (en) 2009-06-18 2014-10-21 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material
GB0913525D0 (en) * 2009-08-03 2009-09-16 Ineos Healthcare Ltd Method
US20120070468A1 (en) 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
AU2012214224B2 (en) * 2011-02-11 2016-03-17 Zs Pharma, Inc Microporous zirconium silicate for the treatment of hyperkalemia
JP5982469B2 (ja) 2011-04-08 2016-08-31 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ アシル化触媒の製造方法
US9527751B2 (en) 2011-11-11 2016-12-27 Basf Se Organotemplate-free synthetic process for the production of a zeolitic material of the CHA-type structure
US20130202524A1 (en) 2012-02-06 2013-08-08 Basf Se Iron- And Copper-Containing Zeolite Beta From Organotemplate-Free Synthesis And Use Thereof In The Selective Catalytic Reduction Of NOx
US9475041B2 (en) 2012-04-24 2016-10-25 Basf Se Zeolitic materials and methods for their preparation using alkenyltrialkylammonium compounds
CA2878832A1 (en) * 2012-07-11 2014-01-16 ZS Pharma, Inc. Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia
RS67365B1 (sr) 2012-10-22 2025-11-28 Zs Pharma Inc Mikroporozni cirkonijum silikat za lečenje hiperkalemije
AU2014248081B2 (en) * 2013-04-05 2019-02-28 ZS Pharma, Inc. Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease
KR102332954B1 (ko) * 2013-11-08 2021-11-29 제트에스 파마, 인코포레이티드 고칼륨혈증의 치료를 위한 미세다공성 규산지르코늄
JP2016540010A (ja) * 2013-12-10 2016-12-22 ズィーエス・ファーマ，インコーポレーテッド リチウム非共投与における高カリウム血症治療用ケイ酸ジルコニウム
US9592253B1 (en) * 2015-10-14 2017-03-14 ZS Pharma, Inc. Extended use zirconium silicate compositions and methods of use thereof

Also Published As

Publication number Publication date
CN108137620A (zh) 2018-06-08
TW201717972A (zh) 2017-06-01
IL258478A (en) 2018-05-31
MX2018004440A (es) 2018-07-06
US11738044B2 (en) 2023-08-29
EA035890B1 (ru) 2020-08-27
AU2016338753B2 (en) 2019-04-18
JP6546700B2 (ja) 2019-07-17
AR106369A1 (es) 2018-01-10
EP3362456A4 (en) 2019-05-15
BR112018007189A2 (pt) 2018-10-16
JP2018530596A (ja) 2018-10-18
EA202091273A1 (ru) 2021-02-03
CN113143958A (zh) 2021-07-23
MY187088A (en) 2021-08-30
ZA201803095B (en) 2019-11-27
TWI742004B (zh) 2021-10-11
IL258478B (en) 2020-09-30
US20240009229A1 (en) 2024-01-11
PH12018500786A1 (en) 2018-10-29
HK1254808A1 (zh) 2019-07-26
US20190365800A1 (en) 2019-12-05
KR20180067614A (ko) 2018-06-20
KR102667566B1 (ko) 2024-05-22
CA3000950C (en) 2023-10-31
AU2016338753A1 (en) 2018-04-12
US9592253B1 (en) 2017-03-14
US10300087B2 (en) 2019-05-28
AU2016338753C1 (en) 2019-08-08
US20170151279A1 (en) 2017-06-01
WO2017066128A1 (en) 2017-04-20
NZ740931A (en) 2024-12-20
CR20180276A (es) 2018-09-19
PH12018500786B1 (en) 2022-09-07
CA3000950A1 (en) 2017-04-20
EP3362456A1 (en) 2018-08-22
CN108137620B (zh) 2021-05-18
EA201890875A1 (ru) 2018-11-30

Similar Documents

Publication Publication Date Title
CL2018000916A1 (es) Composiciones de silicato de zirconio de uso prolongado y métodos de uso de las mismas
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
DOP2017000298A (es) Reguladores de nrf2
CR20180069A (es) Derivados de la sulfamoilarilamida ciclados y su uso como medicamentos para el tratamiento de la hepatitis b
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
MX2017001512A (es) Compuestos activos hacia bromodominios.
MX380866B (es) Composiciones y métodos para modular la expresión del factor b del complemento.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
BR112017008481A2 (pt) composto antimicótico
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
AR100453A1 (es) Composiciones para el cuidado oral que contienen polietilenglicol para estabilidad física
MX2017007371A (es) Compuestos antibacterianos que tienen un amplio espectro de actividad.
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
SV2016005293A (es) Compuestos de azol amido-sustituidos como inhibidores de tnks1 y/o tnks2
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
CR20170498A (es) 2-tiopirimidinonas
MX2016012314A (es) Analagos de apelina ciclicos.
AR097111A1 (es) Combinación y método para la administración a un animal
NI201500172A (es) Composiciones farmacéuticas
AR111017A1 (es) Sal hemisulfato de un compuesto nucleotídico para el tratamiento del virus de la hepatitis c
CR20160175A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa